Pleuropericardial lesion in Q fever.

J. Caughey

DOI: https://doi.org/10.1136/BMJ.1.6074.1447

1977-06-04

British Medical Journal

Abstract:

What problem does this paper attempt to address?

Representation of Patients with Obesity in Atrial Fibrillation Ablation Trials: A Systematic Review

Danielle Dircks,Ahmad Aroudaky,Ei,Muaaz Almerstani,Radha Kanneganti Perue,James Aguto,Jmaylia Mimms,Chenyang Jiang,Lluı́s Mont,Domenico Grieco,Carina Blomström‐Lundqvist,K. V. Davtyan,Sandeep Prabhu,P. Kistler,Arash Aryana,Jason G. Andrade,Laurent Macle,J. William Schleifer,Jason Payne,Arthur R. Easley,Faris Khan,John R. Windle,Shane Tsai,Daniel R. Anderson,Gleb Haynatzki,Thoetchai Peeraphatdit,Niyada Naksuk

DOI: https://doi.org/10.2139/ssrn.4464625

2023-01-01

Abstract:Background: The prevalence and the impact of obesity on outcomes of atrial fibrillation (AF) ablation randomized controlled trials (RCTs) have not been well studied. Objective: To examine the proportion of participants with obesity enrolled in AF RCTs and outcomes of AF ablation when subgroup analysis of participants with obesity were available. Methods: We systematically searched PubMed and EMBASE for AF ablation RCTs published between 01/01/2015 to 05/31/2022. When body mass index (BMI) data were available, normal distribution was assumed and a z-score was used to estimate the proportion of obesity. Results categorized by BMI or body weight status were reviewed. Authors were contacted for additional information. Results: Of 148 eligible RCTs with 30,174 participants, 141 (95.27%) RCTs did not report the proportion of participants with obesity, while published information regarding BMI was available in 63.51%. Three trials excluded patients based on BMI. Using reported BMI, we estimated the proportion of participants with obesity varied greatly across these trials, ranging from 5.82%-71.9% (median 38.02%, interquartile 29.64%, 49.10%). Patients with obesity were represented in a greater proportion among trials conducted in North America (50.23%) and Asia (44.72%), compared to others (32.16%), P<0.001. Subgroup analysis or analysis adjusting for BMI was reported in only 13 (8.78%) RCTs; 4 (30.77%) of these suggested that BMI or body weight might negatively affect primary outcomes. Conclusion: Obesity is a common comorbidity among AF patients. However, most AF ablation RCTs underreported the proportion of participants with obesity and its impact on the main outcomes.
The cross-section of mutual fund fee dispersion

Giuliano Iannotta,Marco A. Navone

DOI: https://doi.org/10.1016/J.JBANKFIN.2011.09.013

2012-03-01

Abstract:
Non-linear Association Between Body Mass Index and Ventricular Tachycardia/Ventricular Fibrillation in Patients With an Implantable Cardioverter-Defibrillator or Cardiac Resynchronization Therapy Defibrillator: A Multicenter Cohort Study

Bin Zhou,Shuang Zhao,Min Tang,Keping Chen,Wei Hua,Yangang Su,Jiefu Yang,Zhaoguang Liang,Wei Xu,Shu Zhang

DOI: https://doi.org/10.3389/fcvm.2020.610629

IF: 3.6

2020-11-30

Frontiers in Cardiovascular Medicine

Abstract:Background: Results from studies on the effects of obesity on sudden cardiac death (SCD) or ventricular tachycardia/ventricular fibrillation (VT/VF) in patients with an implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillator (ICD/CRT-D) are inconsistent. Our study aimed to explore the impact of BMI on VT/VF in patients with an ICD/CRT-D. Methods: We retrospectively analyzed the data from the Study of Home Monitoring System Safety and Efficacy in Cardiac Implantable Electronic Device–implanted Patients in China. Nine hundred and seventy ICD/CRT-D patients were enrolled. The outcome was the first occurrence of VT/VF requiring appropriate ICD/CRT-D therapy. A general linear model and general additive model were used to assess the relationship between BMI and VT/VF. Results: After a median follow-up of 5.17 years, 352 (36.3%) patients experienced VT/VF requiring appropriate ICD/CRT-D therapy. BMI, whether as a continuous variable or a categorical variable classified by various BMI classification criteria, had no significant effect on VT/VF according to a multivariable Cox proportional hazards model with adjustment for potential confounders. However, a non-linear association between BMI and VT/VF was identified using a cubic spline function model and smooth curve fitting. The inflection point for the curve was found at a BMI level of 23 kg/m 2 . The hazard ratios (95% confidence intervals) for VT/VF were 1.12 (1.01–1.24) and 0.96 (0.90–1.02) to the left and right of the inflection point, respectively. Conclusions: BMI is related to VT/VF in a non-linear manner in patients with an ICD/CRT-D. Our research suggests a complicated role of BMI in VT/VF with different impacts at different ranges.

cardiac & cardiovascular systems
Absence of Obesity Paradox in All-Cause Mortality Among Chinese Patients With an Implantable Cardioverter Defibrillator: A Multicenter Cohort Study

Bin Zhou,Xuerong Sun,Na Yu,Shuang Zhao,Keping Chen,Wei Hua,Yangang Su,Jiefu Yang,Zhaoguang Liang,Wei Xu,Min Tang,Shu Zhang

DOI: https://doi.org/10.3389/fcvm.2021.730368

IF: 3.6

2021-12-03

Frontiers in Cardiovascular Medicine

Abstract:Background: The results of studies on the obesity paradox in all-cause mortality are inconsistent in patients equipped with an implantable cardioverter-defibrillator (ICD). There is a lack of relevant studies on Chinese populations with large sample size. This study aimed to investigate whether the obesity paradox in all-cause mortality is present among the Chinese population with an ICD. Methods: We conducted a retrospective analysis of multicenter data from the Study of Home Monitoring System Safety and Efficacy in Cardiac Implantable Electronic Device–implanted Patients (SUMMIT) registry in China. The outcome was all-cause mortality. The Kaplan–Meier curves, Cox proportional hazards models, and smooth curve fitting were used to investigate the association between body mass index (BMI) and all-cause mortality. Results: After inclusion and exclusion criteria, 970 patients with an ICD were enrolled. After a median follow-up of 5 years (interquartile, 4.1–6.0 years), in 213 (22.0%) patients occurred all-cause mortality. According to the Kaplan–Meier curves and multivariate Cox proportional hazards models, BMI had no significant impact on all-cause mortality, whether as a continuous variable or a categorical variable classified by various BMI categorization criteria. The fully adjusted smoothed curve fit showed a linear relationship between BMI and all-cause mortality ( p -value of 0.14 for the non-linearity test), with the curve showing no statistically significant association between BMI and all-cause mortality [per 1 kg/m 2 increase in BMI, hazard ratio ( HR ) 0.97, 95% CI 0.93–1.02, p = 0.2644]. Conclusions: The obesity paradox in all-cause mortality was absent in the Chinese patients with an ICD. Prospective studies are needed to further explore this phenomenon.

cardiac & cardiovascular systems
Feasibility of entirely subcutaneous ICD™ systems in patients with coronary artery disease

Kevin Willy,Markus Bettin,Florian Reinke,Nils Bögeholz,Christian Ellermann,Benjamin Rath,Patrick Leitz,Julia Köbe,Lars Eckardt,Gerrit Frommeyer

DOI: https://doi.org/10.1007/s00392-019-01455-5

Abstract:Background: The subcutaneous ICD (S-ICD™) is an important advance in device therapy for the prevention of sudden cardiac death (SCD). Although current guidelines recommend S-ICD™ use, long-term data are still limited, especially in subgroups. Among several cardiac diseases that prone to SCD, coronary artery disease (CAD) carries several peculiarities that may hamper S-ICD™ therapy in this cohort. CAD can lead to an ischemic cardiomyopathy (ICM) with a reduced left-ventricular ejection fraction (LVEF) and bundle branch blocks, which can be difficult for ICD sensing and discrimination of arrhythmia. CAD is mainly driven by risk factors such as diabetes mellitus, which put these patients at an elevated risk for infectious complications of cardiac devices. Furthermore, in ICM myocardial scars are frequent and are a potential substrate for ventricular tachycardia, which may be accessible for antitachycardia pacing. At the moment, it remains unclear if there is a value of S-ICD™ therapy in this subgroup. Therefore, this study analysed patients with CAD. Materials and methods: All S-ICD™ patients with CAD as the main indication for ICD implantation (n = 45 patients) in our large-scaled single-center S-ICD™ registry (n = 249 patients) were included in this study. Baseline characteristics, appropriate and inappropriate shocks, and complications were documented in a mean follow-up of 22.5 ± 8.3 months. Results: Primary prevention of SCD was the indication for implantation of an S-ICD™ in 28 patients (62%). Of all 45 patients with an overall mean age of 58.1 ± 11.4 years, 40 were male (88%). The mean LVEF was 37.7 ± 12.6%. Three episodes of ventricular arrhythmia (one monomorphic, one polymorphic, one ventricular fibrillation) were adequately terminated in three patients (7%). In only one patient, oversensing resulting in an inappropriate shock was observed, which could be managed by changing the sensing vector. 15 of the examined 45 patients previously had a transvenous ICD, which was explanted due to system-related infections. In only two patients, S-ICD™ was changed to transvenous ICD because of the need of antibradycardia stimulation. There were no S-ICD™ system-related infections. Conclusion: The S-ICD™ seems to be a valuable option for the prevention of SCD in CAD patients. Patients with systemic infections of a transvenous ICD and, therefore, a need for an alternative might benefit from the absence of intracardiac leads as the S-ICD™ is safe and works flawlessly in these patients. Inadequate shock delivery was very rare, while every episode of ventricular arrhythmia was terminated by the first shock.
Implantable Cardioverter Defibrillators for Sudden Cardiac Death Prevention in China: A Regional Analysis from the Improve SCA Clinical Trial

Dejia Huang,Yanchun Liang,Shu Zhang,Zhihui Zhang,Farong Shen,Jingfeng Wang,Liangrong Zheng,Baopeng Tang,Yangang Su,MarkL Brown,BrianM Van Dorn,JanetE O'Brien

DOI: https://doi.org/10.4103/ijhr.ijhr_7_20

2020-01-01

International Journal of Heart Rhythm

Abstract:Background: The improve sudden cardiac arrest (SCA) study was a nonrandomized prospective global study that identified a subset of primary prevention (PP) patients at an elevated risk for SCA labeled 1.5PP. These 1.5PP patients had one or more of the following additional risk factors: Syncope, nonsustained ventricular tachycardia, premature ventricular contractions >10/h, and left ventricular ejection fraction <25%. The purpose of this sub-analysis was to examine the China population cohort according to the improve SCA study's primary and secondary objectives. We aim to analyze the improve SCA study objective outcomes explicitly in the Chinese cohort to better understand the utility of PP implantable cardioverter-defibrillator (ICD) therapy in China. Subjects and Methods: The improve SCA study enrolled patients (n = 4222) during March 2014 and July 2017, including 87 sites in 17 countries from the geographies of Asia, Latin America, Eastern Europe, the Middle East, and Africa. In this analysis, the China cohort of improve SCA patients (n = 1654) was analyzed according to the objectives of the main study; the primary objective compared time to first appropriate ventricular tachycardia (VT) or ventricular fibrillation (VF) therapy between 1.5PP (n = 904) and secondary prevention (SP) patients (n = 470). All-cause mortality rates of 1.5PP with ICDs versus no implant, and an analysis of ischemic versus nonischemic results (n = 280) were also analyzed. PP patients without an additional risk factor were labeled 1.0PP (n = 280). Cox-proportional hazards model was used for hazard ratio (HR) calculations. This study was approved by the Ethics Committee of each participating institution and the associated national and local regulatory agencies, and registered with ClinicalTrials.gov (identifier: NCT02099721). Results: The time to first VT/VF therapy for 1.5PP was not within 30% of SP (HR = 0.42, 95% confidence interval [CI]: 0.31–0.56, P < 0.0001). However, there was a 49% reduction (HR = 0.51, 95% CI: 0.35–0.74, P = 0.0004) in all-cause mortality in the 1.5PP implanted versus nonimplanted patients, and a 70% reduction (HR = 0.30, 95% CI: 0.09–0.99, P = 0.05) in 1.0PP implanted patients. Nonischemic cardiomyopathy (NICM) 1.5PP patients showed a 51% reduction (HR = 0.49, 95% CI: 0.34–0.77, P = 0.0012) in all-cause mortality compared to those who did not receive an ICD implant. Conclusion: The China populations of 1.0PP and 1.5PP patients obtain a significant benefit with implantable defibrillation therapy.
Diagnosis of allied functional bowel disorders using monoclonal antibodies and electronmicroscopy.

P. Puri,T. Fujimoto

DOI: https://doi.org/10.1016/S0022-3468(88)80366-X

IF: 2.549

1988-06-01

Journal of Pediatric Surgery

Abstract:
Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor.

C. Rosendorff,J. Patton,H. M. Radford,B. Kalliatakis

IF: 3.271

Journal of Cardiovascular Pharmacology

Abstract:We investigated pressor sensitivity to infused phenylephrine (PE), 0.05 to 0.4 micrograms/kg/min, and angiotensin II (Ang II), 2.5 to 10 ng/kg/min, in 35 patients with mild-to-moderate hypertension, before and at the end of a 4-week treatment period with the angiotensin-converting enzyme (ACE) inhibitor, cilazapril, 2.5 or 5.0 mg/day. Cilazapril lowered the mean systolic and diastolic blood pressure by 10.6/3.5 mm Hg, but had no effect on the dose-response curves of dose of PE or Ang II vs. the increase in systolic, diastolic, or mean blood pressure, or heart rate. There were also no significant effects of cilazapril on PD20 values, i.e., the dose of PE or Ang II required to increase mean arterial blood pressure (MAP) by 20 mm Hg, or on delta R-R/delta MAP (ratio of the increase of the ECG R-R interval to the increase in mean arterial blood pressure) as a measure of baroreflex sensitivity. Plasma renin activity was significantly increased by cilazapril therapy, but there were no changes in plasma concentrations of Ang II or atrial natriuretic factor. We conclude that cilazapril, an ACE inhibitor, does not alter alpha 1-adrenoceptor and Ang II receptor sensitivity to selective agonists, nor does it affect baroreflex sensitivity.
Granular computing: Common practices and mathematical models

T. Lin

DOI: https://doi.org/10.1109/FUZZY.2008.4630705

2008-06-01

Abstract:A very general formal model is proposed, it formalize almost all the known examples.
Abstract 12506: Implantable Cardioverter Defibrillators for Primary Prevention in Patients With Ischemic and Non Ischemic Cardiomyopathy: A Meta-Analysis of 15 Randomized Controlled Trial

Vikash Jaiswal,Akash Jaiswal,Amira Mohamed Taha,Kriti Kalra,Yusra Nasir

DOI: https://doi.org/10.1161/circ.148.suppl_1.12506

IF: 37.8

2023-11-07

Circulation

Abstract:Background: The evidence to support implantable cardioverter defibrillator (ICD) in patients with ischemic and nonischemic cardiomyopathy for prevention of sudden cardiac death (SCD) is not robust, with conflicting results in randomized controlled trials. Objective: We aim to evaluate the impact of ICD therapy with conventional care for the primary prevention of death of various causes in adults with ischemic and nonischemic cardiomyopathy. Methods: We performed a systematic literature search on the electronic database for relevant articles from inception until 15th May 2022. Results: A total of 15 randomized controlled trials involving 9,999 patients: 9 (6523 patients) addressed ischemic cardiomyopathy, and 6 studies (3476 patients) reported nonischemic cardiomyopathy. The mean follow-up duration was 3.02 years. Pooled analysis showed that ICD therapy significantly reduced the risk of ACM (HR, 0.75(95%CI: 0.64-0.88), P<0.001) from the control group. The magnitude of reduction was similar with ischemic (HR, 0.75(95%CI: 0.58-0.96), P=0.02), nonischemic (HR, 0.76(95%CI: 0.64-0.90), P<0.01). There was 67% reduction in SCD among ICD therapy group (OR, 0.33(95%CI: 0.25-0.44), P<0.00001) compared to the control, a similar trend was observed in both ischemic (OR, 0.39(95%CI: 0.28-0.56), P<0.00001), and nonischemic cardiomyopathy (OR, 0.24(95%CI: 0.15-0.38), P<0.00001). The ICD therapy group had a significant reduction of 65% reduction in arrhythmia-related death compared to control in ischemic cardiomyopathy (OR, 0.35(95%CI: 0.19-0.64), P<0.001). However, there was a trend of 23% in cardiovascular mortality in the ICD group (OR, 0.77(95%CI: 0.58-1.02), P=0.07) but unable to reach statistical significance. Conclusion: Overall, primary prevention with ICD therapy reduced the incidence of all-cause mortality and sudden cardiac death among ischemic and nonischemic cardiomyopathy patients.

cardiac & cardiovascular systems,peripheral vascular disease
Sex-based outcomes of subcutaneous implantable cardioverter-defibrillator and impact of surgical technique

Sonya Vijayvargiya,Wissam Mekary,Vardhmaan Jain,Birju R. Rao,Rand Ibrahim,Anshul M. Patel,Anand D. Shah,David B. DeLurgio,Stacy Westerman,Michael S. Lloyd,Neal Bhatia,Faisal M. Merchant,Mikhael F. El-Chami

DOI: https://doi.org/10.1016/j.hrthm.2024.04.052

IF: 6.779

2024-05-18

Heart Rhythm

Abstract:Background Because of differences in chest wall anatomy, female patients may have higher rates of subcutaneous implantable cardioverter-defibrillator (S-ICD) pocket-related complications. Objective We sought to evaluate sex-based outcomes after S-ICD implantation. Methods Patients implanted with an S-ICD at Emory Healthcare between 2010 and 2023 were included in the analysis. Patients' clinical characteristics and post–S-ICD implantation complications were collected. Results There were 429 male patients (68%) and 199 female patients (32%) observed for a median duration of 2.3 years (0.6–4.4 years). Male and female patients had comparable rates of diabetes (28%), end-stage renal disease (29.5%), ejection fraction (30.2% ± 13.4%), and body mass index (29.1 ± 6.6 kg/m 2 ). There was no statistical difference in the incidence of shocks between men and women (26.3% vs 20.1%; P = .09), including appropriate shocks (14.7% vs 12%; P = .98) and inappropriate shocks (11.7% vs 9.5%; P = .98). Pocket-related complications occurred in 21 patients; these included pocket infection (n = 12), wound dehiscence (n = 7), and hematoma requiring drainage (n = 2). Female patients had a significantly higher pocket-related complication rate compared with male patients (7.2% vs 2.5%; P = .016). In controlling for age, body mass index, diabetes, and end-stage renal disease, female patients had higher odds of pocket-related complications compared with male patients (odds ratio, 3.15; 95% confidence interval, 1.27–7.75). Pocket-related complications decreased after 2018 compared with before 2018 (6% vs 2.6%, P = .052), mainly driven by reduction in complications in women (12.3% vs 3.2%; P = .034) but not in men (2.8% vs 2.4%; P = 1). Conclusion In this cohort of S-ICD patients, women had a higher rate of post–S-ICD pocket-related complications that could be explained by sex-based differences in anatomy.

cardiac & cardiovascular systems
Risk of Appropriate Implantable Cardioverter-Defibrillator Therapies and Sudden Cardiac Death in Patients With Heart Failure With Improved Left Ventricular Ejection Fraction

Mohammed Al-Sadawi,Chad Gier,Michael Tao,Matthew Henriques,Paul Kim,Faisal Aslam,Ibrahim Almasry,Abhijeet Singh,Roger Fan,Eric Rashba

DOI: https://doi.org/10.1016/j.amjcard.2023.06.047

IF: 3.133

2024-02-01

The American Journal of Cardiology

Abstract:BACKGROUND: The benefit of implantable cardioverter-defibrillator (ICD) therapy is controversial in patients who have heart failure with improved left ventricular ejection fraction (EF) to >35% after implantation (HFimpEF).METHODS: Databases (Ovid MEDLINE, EMBASE, Web of Science, and Google Scholar) were queried for studies in patients with ICD that reported the association between HFimpEF and arrhythmic events (AEs), defined as the combined incidence of ventricular arrhythmias, appropriate ICD intervention, and sudden cardiac death (primary composite end point).RESULTS: A total of 41 studies and 38,572 patients (11,135 with HFimpEF, 27,437 with persistent EF ≤35%) were included; mean follow-up was 43 months. HFimpEF was associated with decreased AEs (odds ratio [OR] 0.39, 95% confidence interval [CI] 0.32 to 0.47; annual rate [AR] 4.1% vs 8%, p <0.01). Super-responders (EF ≥50%) had less risk of AEs than did patients with more modest reverse remodeling (EF >35% and <50%, OR 0.25, 95% CI 0.14 to 0.46, AR 2.7% vs 6.2%, p <0.01). Patients with HFimpEF who had an initial primary-prevention indication had less risk of AEs (OR 0.43, 95% CI 0.3 to 0.61, AR 5.1% vs 10.3%, p <0.01). Among patients with primary prevention who had never received appropriate ICD therapy at the time of generator change, HFimpEF was associated with decreased subsequent AEs (OR 0.26, 95% CI 0.12 to 0.59, AR 1.6% vs 4.8%, p <0.01). In conclusion, HFimpEF is associated with reduced, but not eliminated, risk for AEs in patients with ICDs. The decision to replace an ICD in subgroups at less risk should incorporate shared decision making based on risks for subsequent AEs and procedural complications.

cardiac & cardiovascular systems
[Behavioral and biochemical effects of lesions of the raphe on rat-mouse interspecific aggressive behavior].

M. Vergnes,G. Mack,E. Kempf

IF: 3.61

Brain Research

Abstract:
Long-Term Performance of Subcutaneous Implantable Defibrillators in Athletes: A Multicenter, Real-World Analysis of Sport Activities from the iSUSI Registry

Alessio Gasperetti,Marco Schiavone,Julia Vogler,Paolo Compagnucci,Mikael Laredo,Alexander Breitenstein,Simone Gulletta,Martin Martinek,Lukas Kaiser,Carlo Lavalle,Sean Gaine,Luca Santini,Antonio Dello Russo,Pietro Palmisano,Giovanni Rovaris,Antonio Curnis,Nicoletta Ventrella,Jürgen Kuschyk,Mauro Biffi,Roland Tilz,Luigi Di Biase,Claudio Tondo,Giovanni B Forleo,i-SUSI investigators

DOI: https://doi.org/10.1016/j.hrthm.2024.09.039

IF: 6.779

2024-09-20

Heart Rhythm

Abstract:Background: No data regarding subcutaneous-implantable cardioverter defibrillator (S-ICD) technology in patients actively engaging in sports activities are available. Objective: This study aims to compare S-ICD performance between athletes and nonathletes. Methods: The primary outcome of the study was the comparison of overall device-related complications between athletes and nonathletes. Appropriate shocks, inappropriate shocks, and individual device-related complications were secondary outcomes. Results: A total of 1493 patients were extracted from the International Subcutaneous Implantable Cardioverter Defibrillator Registry (iSUSI) registry, of whom 152 (10.2%) were athletes, mostly engaging in dynamic sports (54.2%). Brugada syndrome, myocarditis, and arrhythmogenic right ventricular cardiomyopathy (ARVC) were more common in athletes (11.2% vs 3.3%, P < .001; 19.1% vs 9.0%, P < .001; 8.6% vs 2.8%, P < .001, respectively). During a median follow-up time of 25.5 (12.0-41.2) months, athletes were more likely to experience appropriate shocks (yearly rate: 7.2 [4.9-10.7] % vs 4.3 [3.6-5.1] %, P = .028), occurring more frequently during exercise (3.9% vs 0.6%, P < .001). This finding lost significance when adjusting for confounders (adjusted hazard ratio [aHR] 1.440 [0.909-2.281], P = .120). No differences were found in overall device-related complications (yearly rate: 3.3% vs 3.4%, P = .448) and inappropriate shocks (yearly rate: 5.3% vs 3.7%, P = 0.111). Myopotential oversensing (4.0% vs 1.3%, P = .011) was more common in athletes, as were lead infections (3.3% vs 0.9%, P =.008), with the latter clustering in the early postimplantation period. Conclusion: The S-ICD is a valid therapeutic option for preventing sudden cardiac death in athletes. Sports practice was not associated with an increased risk of complications or inappropriate shocks, although athletes are exposed to a higher risk of S-ICD infections in the early postoperative period.
Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

Mohammad Abumayyaleh,Katharina Koepsel,Julia W. Erath,Thomas Kuntz,Norbert Klein,Boldizsar Kovacs,Firat Duru,Ardan M. Saguner,Christian Blockhaus,Dong‐In Shin,Fabienne Kreimer,Michael Gotzmann,Hendrik Lapp,Thomas Beiert,Assem Aweimer,Andreas Mügge,Christel Weiß,Ibrahim El‐Battrawy,Ibrahim Akin

DOI: https://doi.org/10.1002/ehf2.15141

2024-11-01

ESC Heart Failure

Abstract:Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an 'obesity paradox' has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored. Methods In a multicentre international registry, we retrospectively collected data from a consecutive series of 1003 patients. These patients were divided into three body mass index (BMI) groups: 30 kg/m2 (n = 272), with BMI > 30 kg/m2 defined as the reference category. Demographics, indications, adherence, WCD shocks, arrhythmic events, rehospitalization due to cardiovascular causes, and mortality were analysed. Results At 3 month follow‐up, patients with a BMI > 30 showed the greatest improvement in left ventricular ejection fraction (LVEF) at 51.4%, significantly higher than the 41.4% in those with a BMI 30 group (36.8%) compared with others, although not significantly. Rehospitalization due to cardiovascular causes was significantly lower in the BMI > 30 group (55.4%) compared with the BMI 25–30 group (70.9%; P = 0.048), but similar to the BMI 30 group (5.9%) compared with the BMI

cardiac & cardiovascular systems
Picosecond fluorescence from photosynthetic systems in vivo.

G. Searle,C. Tredwell

DOI: https://doi.org/10.1002/9780470720431.CH14

1978-02-07

Abstract:Picosecond time-resolved fluorescence emission from the pigments of intact photosynthetic systems and isolated pigment-protein fractions has been used to probe the mechanism of energy transfer and the organization of the pigments. The fluorescence kinetics of chlorophyll and the phycobilins of the red alga, Porphyridium cruentum, are governed by time-dependent kinetics, but the observed time dependence of the chlorophyll a fluorescence decay from dark-adapted Chlorella pyrenoidosa and spinach sub-chloroplast fractions is still open to conjecture. In contrast to the green plants containing only chlorophyll and carotenoids, Porphyridium shows distinct emission bands for each the pigments in the transfer sequence. The rate of energy transfer in vivo has the empirical form: dS/dt = -1/2S At-1/2, where S is the excited-state population of the donor pigment and A is the overall rate of energy transfer to the acceptor pigment. The kinetic analysis can describe closely the observed fluorescence risetimes and lifetimes of the photosynthetic pigments of Porphyridium. The extremely rapid rates of energy transfer, determined by this treatment, imply that exciton migration within each pigment bed of the phycobilisome is less extensive than in the chlorophyll-antenna systems. Changes in the fluorescence yield and decay kinetics of chlorophyll a and allophycocyanin in vivo can be induced at high excitation intensities by exciton-exciton annihilation.
Obesity paradox in patients with reduced ejection fraction eligible for device implantation – an observational study

Eperke D. Merkel,Anett Behon,Richard Masszi,Walter R. Schwertner,Luca Kuthi,Boglárka Veres,István Osztheimer,Roland Papp,Levente Molnár,Endre Zima,László Gellér,Annamária Kosztin,Béla Merkely

DOI: https://doi.org/10.1002/ehf2.14961

2024-07-20

ESC Heart Failure

Abstract:Aims Patients with obesity have an overall higher cardiovascular risk, at the same time obesity could be associated with a better outcome in a certain subgroup of patients, a phenomenon known as the obesity paradox. Data are scarce in candidates for cardiac resynchronization therapy (CRT). We aimed to investigate the association between body mass index (BMI) and all‐cause mortality in patients eligible for CRT. Methods Altogether 1,585 patients underwent cardiac resynchronization therapy between 2000–2020 and were categorized based on their BMI, 459 (29%) patients with normal weight (BMI

cardiac & cardiovascular systems
A single-center analysis of the safety and efficiency of subcutaneous implantable cardioverter defibrillator implantation technique

李明辉,张磊,梁义秀,汪菁峰,陈学颖,柏瑾,秦胜梅,王蔚,宿燕岗,葛均波

DOI: https://doi.org/10.3760/cma.j.cn.113859-20200902-00227

2020-01-01

Abstract:Objective:To evaluate the safety and efficiency of the subcutaneous implantable cardioverter defibrillator (S-ICD) system to provide evidence for its widespread in clinical practice.Methods:Consecutively enroll patients prepared to receive S-ICD implantation from August 2018 to August 2020 in Department of Cardiology, Zhongshan Hospital of Fudan University. Twenty-four patients received S-ICD implantation, among which 21 cases were male and 3 female with an average age of (41±18) years. The patients’ basic cardiovascular diseases spectrum was summarized and analyzed. The electrocardiogram (ECG) screening before implantation, the implantation techniques, the study curve characteristics and the complication post implantation were retrospectively studied. The follow-up data until August 30, 2020 were analyzed to evaluate preliminarily the safety and efficiency of S-ICD.Results:A total of 25 patients were prepared for S-ICD implantation, but one case failed in the ECG screening before surgery. And the other 24 patients received the S-ICD implantation. The basic cardiovascular diseases spectrum included 10 cases of dilated cardiomyopathy (10/24, 41.7%) , 4 ion channel diseases (4/24, 16.7%) , 6 hypertrophy cardiomyopathy (6/24, 25%) , 1 ischemic heart disease (1/24, 4.2%) and 3 others (3/24, 12.5%) . The implantation surgical technique learning curve was short with an average time consumption of (55.0±18.7) min. The complications were rare under the standard operation procedure so far. Seventeen events were recorded in routine follow-up. There were 6 discharge events, 4 of which were handled correctly with 100% successful one-time defibrillation and 2 of inappropriate discharges. After program control treatment, there was no inappropriate discharge recurrence, indicating the safety and efficiency of the S-ICD system.Conclusion:Based on our single-center experiences, S-ICD implantation technique had relatively short learning curve with fewer complications, and was safe and efficient for the prevention of sudden cardiac death.
Gender differences in appropriate shocks and mortality among patients with primary prophylactic implantable cardioverter-defibrillators: Systematic review and meta-analysis

David Conen,Barbora Arendacká,Christian Röver,Leonard Bergau,Pascal Muñoz,Sofieke Wijers,Christian Sticherling,Markus Zabel,Tim Friede

DOI: https://doi.org/10.1371/journal.pone.0162756

2016-09-16

Abstract:BACKGROUND: Some but not all prior studies have shown that women receiving a primary prophylactic implantable cardioverter defibrillator (ICD) have a lower risk of death and appropriate shocks than men. PURPOSE: To evaluate the effect of gender on the risk of appropriate shock, all-cause mortality and inappropriate shock in contemporary studies of patients receiving a primary prophylactic ICD. DATA SOURCE: PubMed, LIVIVO, Cochrane CENTRAL between 2010 and 2016. STUDY SELECTION: Studies providing at least 1 gender-specific risk estimate for the outcomes of interest. DATA EXTRACTION: Abstracts were screened independently for potentially eligible studies for inclusion. Thereby each abstract was reviewed by at least two authors. DATA SYNTHESIS: Out of 680 abstracts retained by our search strategy, 20 studies including 46'657 patients had gender-specific information on at least one of the relevant endpoints. Mean age across the individual studies varied between 58 and 69 years. The proportion of women enrolled ranged from 10% to 30%. Across 6 available studies, women had a significantly lower risk of first appropriate shock compared with men (pooled multivariable adjusted hazard ratio 0.62 (95% CI [0.44; 0.88]). Across 14 studies reporting multivariable adjusted gender-specific hazard ratio estimates for all-cause mortality, women had a lower risk of death than men (pooled hazard ratio 0.75 (95% CI [0.66; 0.86]). There was no statistically significant difference for the incidence of first inappropriate shocks (3 studies, pooled hazard ratio 0.99 (95% CI [0.56; 1.73]). CONCLUSION: In this large contemporary meta-analysis, women had a significantly lower risk of appropriate shocks and death than men, but a similar risk of inappropriate shocks. These data may help to select patients who benefit from primary prophylactic ICD implantation.

Medical Physics,Quantitative Methods,Applications
long term follow up of Implantable Cardioverter Defibrillators (ICD) in hypertrophic cardiomyopathy: is subcutaneous the way forward?

C Monkhouse,J Maclolmson,L Sevier,J Platten,M Dhinoja,A Chow,S Honarbakhsh,R Schilling,R Hunter,P D Lambiase,S Ahsan,S Mohiddin

DOI: https://doi.org/10.1093/eurheartj/ehae666.721

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Introduction Young patients have greater risks of longer-term complications including inappropriate therapy (IT) from Implantable Cardioverter Defibrillators (ICD) than older ICD patients. In prevention of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM), these complications are critical in determining treatment thresholds. When comparing transvenous ICDs (TV), subcutaneous ICDs (SICD) may have different risks & benefits that define their relative utility. We investigated TV & SICD outcomes in a propensity matched cohort of HCM patients. Methods We used electronic health records in a retrospective study of HCM patients receiving an ICD between 2006-22 at tertiary centre. Indications for ICD implantation, including type of device, were determined by the treating cardiomyopathy team according to ESC guidance. All TV device types were included & eligibility for SICD included passing screening in at least 1 sensing vector. Outcome data included patients lost to follow-up until the last device check & patients who had both device types were included twice. Patients were censored after their first IT for an analysis of IT, & their first 'ICD complication' for that analysis. ICD complications are defined as all other complications that resulted in a re-intervention procedure (excl SICD battery advisory), or extra procedure at box change. The audit was registered with local institutional review board for ethical approval. Propensity scoring was used for stratification and covariate adjustment. Matching was conducted using the 12 baseline variables. Associations with IT, ICD complications and their composite were assessed using proportional hazard regression (Cox) models, with time to event starting at implant date. Univariable & multivariable regression analyses were used as appropriate. Hazard ratios (HRs) of 95% confidence intervals were estimated by fitting a model with the propensity score and dichotomous variable (TV vs SICD). A p value of <0.05 was considered statistically significant. Analyses were conducted using R- Version 2023.06.0+421. Results Mean age was 55±14.2 years with follow-up of 73±63 months; 70.7% were male. Of a total of 611 patients, with 469 in the TV group & 164 in the SICD. SICD patients had fewer complications, with no differences in IT across all and propensity matched analyses (CI 0.64), fig 1. Conclusion In HCM, when compared to TV, SICDs are associated with fewer ICD complications & not associated with more frequent IT. Intriguingly, there was a higher rate of IT with the first generation SICD, causing the wide IT errors at longer durations. Complications over long term follow up require more assessment, but the absence of TV lead intervention creates reduced risks for SICD complications. In HCM patients without pacing needs, SICDs may be preferred for HCM-SCD prevention. In addition, the lower risks associated with SICD could lead to lower treatment thresholds for people with elevated lifetime HCM-SCD risk.

cardiac & cardiovascular systems

Pleuropericardial lesion in Q fever.

Representation of Patients with Obesity in Atrial Fibrillation Ablation Trials: A Systematic Review

The cross-section of mutual fund fee dispersion

Non-linear Association Between Body Mass Index and Ventricular Tachycardia/Ventricular Fibrillation in Patients With an Implantable Cardioverter-Defibrillator or Cardiac Resynchronization Therapy Defibrillator: A Multicenter Cohort Study

Absence of Obesity Paradox in All-Cause Mortality Among Chinese Patients With an Implantable Cardioverter Defibrillator: A Multicenter Cohort Study

Feasibility of entirely subcutaneous ICD™ systems in patients with coronary artery disease

Implantable Cardioverter Defibrillators for Sudden Cardiac Death Prevention in China: A Regional Analysis from the Improve SCA Clinical Trial

Diagnosis of allied functional bowel disorders using monoclonal antibodies and electronmicroscopy.

Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor.

Granular computing: Common practices and mathematical models

Abstract 12506: Implantable Cardioverter Defibrillators for Primary Prevention in Patients With Ischemic and Non Ischemic Cardiomyopathy: A Meta-Analysis of 15 Randomized Controlled Trial

Sex-based outcomes of subcutaneous implantable cardioverter-defibrillator and impact of surgical technique

Risk of Appropriate Implantable Cardioverter-Defibrillator Therapies and Sudden Cardiac Death in Patients With Heart Failure With Improved Left Ventricular Ejection Fraction

[Behavioral and biochemical effects of lesions of the raphe on rat-mouse interspecific aggressive behavior].

Long-Term Performance of Subcutaneous Implantable Defibrillators in Athletes: A Multicenter, Real-World Analysis of Sport Activities from the iSUSI Registry

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

Picosecond fluorescence from photosynthetic systems in vivo.

Obesity paradox in patients with reduced ejection fraction eligible for device implantation – an observational study

A single-center analysis of the safety and efficiency of subcutaneous implantable cardioverter defibrillator implantation technique

Gender differences in appropriate shocks and mortality among patients with primary prophylactic implantable cardioverter-defibrillators: Systematic review and meta-analysis

long term follow up of Implantable Cardioverter Defibrillators (ICD) in hypertrophic cardiomyopathy: is subcutaneous the way forward?